Similarly, the expressions of the NLRP3 pathway target genes IL-1β and IL-18 were also increased in the BC group, while pre-treatment with LGR-1 attenuated the BC-induced expression of IL-1β and IL-18 (Fig. 3C, P< 0.01). Here, NLRP3 is linked to breast cancer.